Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESSO 43 | Integrating patient-centered objectives into clinical research to prioritize QoL outcomes

Laura Lorenzon • 3 Oct 2024
ESSO 43
General

Laura Lorenzon, MD, PhD, Policlinico Universitario Agostino Gemelli, Rome, Italy, emphasizes the importance of enhancing patients’ quality of life by incorporating their perspectives into clinical research objectives. She advocates for greater patient involvement in defining research goals to ensure outcomes align with their needs. This interview took place at the ESSO 43 congress in Antwerp, Belgium.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Laura Lorenzon

Addressing disparities in access to molecular testing, liquid biopsy, & fertility care across Europe
0:41
Addressing disparities in access to molecular testing, liquid biopsy, & fertility care across Europe
Laura Lorenzon • 3 Oct 2024
Incorporating patient perspectives into clinical research to improve quality of life in cancer care
0:39
Incorporating patient perspectives into clinical research to improve quality of life in cancer care
Laura Lorenzon • 3 Oct 2024
Prioritizing quality of life in cancer care to align treatment with patients’ well-being goals
0:41
Prioritizing quality of life in cancer care to align treatment with patients’ well-being goals
Laura Lorenzon • 3 Oct 2024
Impact of malnutrition in gastrointestinal cancer: early detection and intervention are key
1:01
Impact of malnutrition in gastrointestinal cancer: early detection and intervention are key
Laura Lorenzon • 3 Oct 2024

Related Videos

AI governance and validation in robotic cancer surgery
1:12
AI governance and validation in robotic cancer surgery
Marie Hanaoka • 1 Jul 2026
Does toxicity differ between patients treated with SABR for one versus five lesions?
0:39
Does toxicity differ between patients treated with SABR for one versus five lesions?
Robert Olson • 16 May 2026
5-year toxicity following SABR: insights from the SABR-5 trial
0:42
5-year toxicity following SABR: insights from the SABR-5 trial
Robert Olson • 16 May 2026
How should results from the SABR-5 trial guide future SABR studies?
1:05
How should results from the SABR-5 trial guide future SABR studies?
Robert Olson • 16 May 2026
The content of VJOncology is intended for healthcare professionals